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httpcense.Abstract Introduction: Systemic lupus erythematosus (SLE) is a disorder of immune regulation
where cytokine imbalance and genetic factors are implicated in its pathogenesis.
Aim of the work: To evaluate the clinical signiﬁcance of serum levels of tumor necrosis factor
alpha (TNFa) and its -308 G/A promoter polymorphism as well as the IL-6 and -174 promoter
polymorphism in SLE patients and ﬁnd any association to the clinical and laboratory features as
well as to the disease activity and severity.
Patients and methods: We studied 37 female SLE patients and age and gender matched healthy
control. Demographic, clinical and serological data were evaluated and the Systemic Lupus Erythe-
matosus Disease Activity Index (SLEDAI) and the Systemic Lupus International Collaboration
Clinics/ACR Damage Index (SLICC) were assessed. Serum TNF-a and IL-6 levels were measured
using enzyme-linked immunosorbent assay (ELISA) and DNA genotyped for TNF-a promoter
(-308 G/A) and IL-6 promoter (-174 G/C) by polymerase-chain reaction-restriction fragment-length
polymorphism (PCR-RFLP) analysis.38956697, mobile: +20
om (G.S. Azkalany).
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120 G.S. Azkalany et al.Results: Serum TNF-a and IL-6 levels were signiﬁcantly higher in the SLE patients compared to
control. Regarding IL-6, there was a statistically signiﬁcant difference between the levels in the three
groups according to the promoter polymorphisms. Patients with constitutional symptoms showed
higher level of IL-6 while the TNF-a level was signiﬁcantly lower in those with pulmonary manifes-
tations. There was a tendency to a higher TNF-a and IL-6 level in those with neuropsychiatric man-
ifestations.
Conclusion: Serum TNF-a, -308 G/A promoter polymorphism, IL-6 and -174 G/C were higher
in SLE patients than in healthy controls. To conﬁrm our results we propose that larger scale, mul-
ticenter studies with longer evaluation periods are needed.
 2012 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
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Systemic lupus erythematosus (SLE) is a disorder of immune
regulation resulting in chronic inﬂammation that affects many
organs with the production of autoantibodies [1,2]. The cause
of lupus is not known, but genes play a signiﬁcant role in its pre-
disposition. The major histocompatibility complex (MHC) on
chromosome 6 contains at least 100 different genes that affect
the immune system, including the genes with the strongest effect
on lupus susceptibility and the identity of these actual genes has
remained elusive [3,4]. Cytokine unbalance is responsible for the
pathogenesis of diverse inﬂammatory, autoimmune and infec-
tious diseases [5] and genetic factors are implicated in this path-
ogenesis [6].
TNF-a 308A was found to be an independent susceptibility
factor [6]. TNF-amay be detrimental in SLE, by both inducing
inﬂammation and apoptosis, which could fuel the autoimmune
response [2]. The polymorphism of the TNF-a 308 promoter
gene has been implicated as a genetic risk factor for SLE in
some populations [1,2,7–9]. Yet, it is unclear as to whether
the role of TNF-a as a mediator of inﬂammation is a beneﬁcial
or deleterious one in the susceptibility to SLE [2].
The production of a regulator of the inﬂammatory reaction,
TNF-a, has been found to be deeply dysregulated in SLE, sug-
gesting that it may be involved in the pathogenesis of the dis-
ease. Its involvement in the pathogenesis is more controversial
although most investigators found increased serum levels. Ge-
netic polymorphisms at the promoter of TNF-a gene have
been associated with different forms of cytokine production
[1]. TNF-a stimulates cytokine production and enhances
expression of adhesion and even though its importance in
the pathogenesis of SLE is unclear, minor differences in its
production can inﬂuence upon the resulting autoimmune dis-
ease [2]. The increase of TNF-a in SLE and the development
of antinuclear antibodies (ANA) and anti-DNA antibodies,
and an SLE-like illness in some patients treated with TNF
antagonists lead some to suspect that the TNF-a axis may
be important in susceptibility [10].
The TNF-a -308 polymorphism has been linked to in-
creased susceptibility to and severity in a variety of autoim-
mune and inﬂammatory disorders, including RA, SLE and
inﬂammatory bowel disease [5,11,12].
Interleukin-6 (IL-6) is a cytokine that can facilitate autoim-
mune phenomena, amplify acute inﬂammation and promote
the evolution into a chronic inﬂammatory state. In addition,
IL-6 has a pivotal role in synovitis and in the systemic features
of inﬂammation [13]. The transition from acute to chronicinﬂammation is characterized by a change in cellular inﬁltrate
from predominantly polymorphonuclear neutrophils to mono-
nuclear cells, and IL-6 is a key regulator of this process [14] .
Gene polymorphisms such as those located at TNF, IL-1
and IL-6 seem to be responsible for more aggressive disease
phenotype. The efforts in the post-genomic era can bring to
an estimation of the real likelihood of the genetic effect [15].
Despite the important physiological activities of IL-6, dysreg-
ulated overproduction is pathologically involved in various im-
mune-mediated inﬂammatory diseases such as SLE [16]. The
discovery of new genes associated with the disease can be rel-
evant in ﬁnding potential biomarkers, potentially useful in dis-
ease diagnosis and treatment [15].
Aim of the present study was to evaluate the clinical signiﬁ-
cance of serum levels of tumor necrosis factor alpha (TNF-a)
and -308 G/A promoter polymorphism as well as IL-6 and -
174G/Cpromoter polymorphism in systemic lupus erythemato-
sus (SLE) patients and ﬁnd any association to the clinical and
laboratory features as well as to the disease activity and severity.
2. Patients and methods
Thirty-seven female SLE patients fulﬁlling the updated Ameri-
can College of Rheumatology (ACR) revised criteria for the
classiﬁcation of SLE [17] were consecutively recruited from
the Rheumatology Department, Cairo University Hospitals.
Fifteen age matched female controls were also included. Those
with juvenile onset disease were considered when the disease
started before the age of 16. Full history taking, thorough clin-
ical examination and laboratory investigations were done for all
patients. Assessment of disease activity was assessed using the
Systemic Lupus Erythematosus Activity Index (SLEDAI) [18],
disease damage using the Systemic Lupus International Collab-
oration Clinics/ACR Damage Index (SLICC/DI) [19]. Renal
biopsies were done in those with renal involvement, the speci-
mens processed for light microscopy and classiﬁed according
to the 1982 modiﬁed WHO morphologic classiﬁcation of lupus
nephritis [20]. Informed consents were taken from the patients
and the study was approved by the local ethical committee.
2.1. Serum TNF-a
Serum TNF-a level: Serum TNF-a was assayed using Human
TNF-a ELISA kit (quantitative sandwich enzyme immunoas-
say technique), provided by Ray Biotech, Inc.
Determination of TNF-a gene (-308) promoter region
polymorphism: Promoter region polymorphism of TNF-a gene
Clinical signiﬁcance of serum TNFa and -308 G/A promoter polymorphism 121(-308G/A) was determined by polymerase-chain reaction-
restriction fragment polymorphism (PCR-RFLP) technique.
DNA isolation and TNF-a genotyping: Genomic DNA was
isolated from white blood cells (WBCs) of peripheral blood
using Biospin Whole Blood Genomic DNA Extraction Kit
(Bioﬂux Corporation, Arrow Plaza, Tokyo, Japan). Enzymatic
ampliﬁcation was performed by PCR using Master Taq
polymerase enzyme and Hybaid thermal cycler (Promega Cor-
poration, 2800 Woods Hollow Road, Madison, WI 153711-
5399, USA). Ampliﬁcation of the promoter region (-308G/A)
of the TNF-a gene as proposed by Dalziel et al. [21] using
two primers were purchased from Operon Biotechnologies
(GmbH/Biocampus, Germany). Forward Primer: 50-AGGCA
ATAGGTTTTGAGGGCCAT-30, and Reverse Primer: 50-A
CACTCCCCATCCTCCCTGCT-30. The PCR reaction mix-
ture (25 ll) contained 12.5 ll 2· PCR Master Mix {10· PCR
buffer, 4 mM MgCl2, 0.5 Taq DNA polymerase/ll, 0.4 mM
dNTPs (dATP, dCTP, dGTP, dTTP)}, 1 ll of each primer
(25 pmol), 3 ll of genomic DNA and 7.5 ll sterilized nucle-
ase-free water. The reaction was carried out with the following
cycles: 95 C for 2 min; 35 cycles of 95 C for 30 s, 60 C for
15 s and 74 C for 15 s; and 74 C for 10 min for ﬁnal exten-
sion. Then ampliﬁed products were digested with ﬁve units
Fast Digest NcoI restriction enzyme at 37 C for 10 min (sup-
plied by Fermentas, LT-02241 Vilnius, Lithuania). The di-
gested products were then detected in 3.5% agarose gel
containing ethidium bromide by performing E/P on the gel
electrophoresis apparatus and visualized by UV transillumina-
tion (Promega, USA) for identiﬁcation of TNF-a gene (-308G/
A) promoter polymorphism. A single band at 107 bp identiﬁed
AA homozygous individuals, two bands at 87 and 20 bp iden-
tiﬁed GG homozygous individuals, and three bands at 107, 87
and 20 bp indicated a heterozygote at the TNF-a-308 locus,
while the 20 bp band was very small to be viewed on the gel.
2.2. Serum IL-6
Serum IL-6 level: Serum IL-6 was assayed using Human IL-6
ELISA kit (quantitative sandwich enzyme immunoassay tech-
nique), provided by Ray Biotech, Inc.
Determination of IL-6 gene (-174) promoter polymorphism:
Promoter region polymorphism of IL-6 gene (-174 G/C) was
determined by polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) technique. DNA isolation
and IL-6 genotyping: Genomic DNA was isolated from white
blood cells (WBCs) of peripheral blood using Biospin Whole
Blood Genomic DNA Extraction Kit (Bioﬂux Corporation,
Arrow Plaza, Tokyo, Japan). Enzymatic ampliﬁcation was per-
formed by PCR using Master Taq polymerase enzyme and
Hybaid thermal cycler (Promega Corporation, 2800 Woods
HollowRoad,Madison,WI 153711-5399, USA). Ampliﬁcation
of the promoter region (-174G/C) of the IL-6 gene was done [22]
using two primers (were purchased from Operon Biotechnolo-
gies (GmbH/Biocampus, Germany). Forward Primer: 50-GCC
TCA ATG ACG ACC TAA GC-30, and Reverse Primer: 50-
TCA TGG GAA AAT CCC ACA TT-30. The PCR reaction
mixture (25 ll) contained 12.5 ll 2· PCR Master Mix {10·
PCR buffer, 4 mM MgCl2, 0.5 Taq DNA polymerase/ll,
0.4 mM dNTPs (dATP, dCTP, dGTP, dTTP)}, 1 ll of each pri-
mer (25 pmol), 3 ll of genomic DNA and 7.5 ll sterilized nucle-
ase-free water. The reaction was carried out with the followingcycles: 95 C for 5 min; 35 cycles of 30 s denaturation at 95 C,
30 s annealing at 61 C and 30 s extension at 72 C and a 10-
minute ﬁnal extension at 72 C after completion of the cycles.
Then ampliﬁed products were digested with ﬁve units Fast Di-
gest NLa III restriction enzyme at 37 C for 10 min (supplied by
Fermentas, LT-02241 Vilnius, Lithuania). The digested
products were then detected in 3.5% agarose gel containing
ethidium bromide by performing E/P on the gel electrophoresis
apparatus and visualized by UV transillumination (Promega,
USA). A single band at 163 bp identiﬁed GG homozygous indi-
viduals, two bands at 111 and 52 bp identiﬁed CC homozygous
individuals, and three bands at 163, 111 and 52 bp indicated a
GC heterozygote.
Statistical analysis: The data were collected, tabulated and
analyzed by SPSS package version 15 (SPSS Corporation,
USA). Data was summarized as mean ± SD. Mann–Whitney
tests was used for comparative analysis of two quantitative
data. Non-parametric analysis of variance (Kruskall–Wallis)
was used for comparison of more than two groups; Spear-
man’s correlation analysis was used for detection of the rela-
tion between two variables. Logistic regression analysis was
applied to detect the predictors for the elevated TNF-a level
and promoter polymorphism. Results were considered signiﬁ-
cant at p< 0.05.
3. Results
There were 37 female SLE patients and 15 age matched healthy
female control with a mean age of 28.93 ± 2.69 years. The
demographic features, clinical manifestations, disease activity
indices and damage indices are presented in Table 1. All the pa-
tients were receiving corticosteroids (17.28 ± 8.99 mg/day), 31/
37 were receiving hydroxychloroquine, 17 cyclophosphamide
and 24 azathioprine. One of the patients was diabetic and hyper-
tension was present in 14/37 patients. None of the patients gave
family history for any rheumatic disease.
Comparing the mean TNF-a level of the patients
(5.39 ± 14.98 pg/ml) to the control group (0.38 ± 0.23 pg/ml)
there was a slight signiﬁcant difference (p-value 0.049). How-
ever, there were promoter polymorphisms in the patients group
while all the control had GG promoter. The mean serum IL-6
was signiﬁcantly higher in the patients (32.07 ± 52.22 pg/ml)
compared to the control (7.56 ± 7.18 pg/ml) (p-value 0.008).
There were 35/37 (94.6%) with GG TNF-a (-308 G/A) gene
promoter polymorphism and 5.4%with GA while it was GG in
all the control. There were 29/37 (78.38%) with GG IL-6 (-174
G/C) with 16.2% with GC and 5.4% with CC promoter. Fig. 1
shows the PCR-based RFLP analysis of TNF-a (-308G/A) and
Il-6 (-174 G/C) gene polymorphism.
Regarding the TNF-a, the two patients with GA promoter
had a higher mean serum level (57.1 ± 40.87 pg/ml) vs
2.43 ± 4.69 pg/ml for those with GG promoter. As for the
IL-6, there was a statistically signiﬁcant difference between
the level in the three groups according to the promoter polymor-
phism (p-value 0.000) being 13.23 ± 16.4 pg/ml for those with
GG promoter, 64.17 ± 36.16 pg/ml for GC promoter and
209 ± 70.71 pg/ml in those with CC promoter.
There was a signiﬁcant difference in the disease duration
according to the three TNF-a gene promoters (p-value 0.024)
being longer in those with AA (13.5 ± 9.19 years) compared
to those with GG (6.14 ± 5.06 years) and those with GA
Table 1 Demographic features, disease activity and damage
indices, laboratory investigations and clinical manifestations of
the SLE patients.
Parameter SLE patients (37) (mean ± SD)
Age (years) 27.4 ± 6.99
Age at onset (years) 21.52 ± 7.45
Disease duration (years) 5.9 ± 5.29
ESR (mm/1st hour) 60.66 ± 36.53
Hemoglobin (g/dl) 10.97 ± 1.97
WBCs (·103/mm3) 6.73 ± 3.22
Platelets (·103/mm3) 262.54 ± 99.94
AST (U/l) 20.26 ± 14.23
ALT (U/l) 26.53 ± 23.83
Creatinine (mg/dl) 0.84 ± 0.74
Albumin (gm/dl) 3.69 ± 0.64
Urine protein (gm/24 h) 0.63 ± 0.76
TNF-a (pg/ml) 5.39 ± 14.98
IL-6 (pg/ml) 32.07 ± 52.22
SLEDAI 6.26 ± 8.28
SLICC 0.74 ± 1.39
Parameter no. (%)
ANA 36(97.3)
Anti-ds DNA 25(67.6)
ACL 14(37.8)
Constitutional manifestations 25(67.6)
Mucocutaneous manifestations 35(94.6)
Arthritis 35(94.6)
Hematological manifestations 17(45.9)
Nephritis 24(64.9)
Neuropsychiatric manifestations 12(32.4)
Cardiovascular manifestations 1(2.7)
Pulmonary manifestations 5(13.5)
Serositis 20(54)
APS 9(24.3)
Vasculitis 10(27)
ESR: erythrocyte sedimentation rate, WBCs: white blood cells,
AST: aspartate transaminase, ALT: alanine transaminase, TNF-a:
tumor necrosis factor-a, IL-6: Interleukin-6, SLEDAI: Systemic
Lupus Erythematosus Disease Activity Index. SLICC: Systemic
Lupus International Collaborating Clinics, ANA: Anti nuclear
antibodies, Anti-ds DNA: anti double stranded, ACL: anti cardi-
olipin, APS: Antiphospholipid syndrome.
Figure 1 PCR-based RFLP analysis of (a) TNF-a (-308G/A) gene
genotype. Lanes (3 and 4): GA genotype. Lanes (1 and 2): AA genot
DNA ladder. Lanes (1, 3 and 5): GG genotype. Lanes (2 and 4): GC
122 G.S. Azkalany et al.(2.22 ± 1.23 years). There were no other signiﬁcant differences
in the characteristic features of the patients according to the
promoter genes. There were no signiﬁcant correlations of the
serum TNF-a or IL-6 with the clinical or laboratory features
of the patients or according to the anti-ds DNA positivity.
According to the presence or absence of clinical manifesta-
tions, there was a tendency to a higher level of IL-6 in those with
constitutional symptoms (47.5 ± 65.03 pg/ml vs 15.47 ±
23.99 pg/ml; p 0.064) while the TNF-a level was signiﬁcantly
lower in those with pulmonary manifestations compared to
those without (p-value 0.035). There was a tendency to a higher
TNF-a and IL-6 level in those with neuropsychiatric manifesta-
tions (11.4 ± 24.81 pg/ml and 54.38 ± 79.47 pg/ml, respec-
tively, compared to those without (2.5 ± 5.24 pg/ml and 21.3
6 ± 28.76, respectively) (p-value 0.24 and 0.19, respectively).
There were seven juvenile onset SLE patients and 30 Adult
onset. There was no signiﬁcant difference in the TNF-a or IL-6
levels according to the age at disease onset. However there was
a tendency for a higher level of both in the Juvenile onset SLE
patients (5.86 ± 10.37 pg/ml vs 5.28 ± 16 and 50.81 ± 94 pg/
ml vs 27.7 ± 38.1 pg/ml, respectively).
4. Discussion
In this current study, the mean TNF-a levels were signiﬁcantly
higher in SLE patients compared to normal controls and there
were promoter polymorphisms in SLE patients while all con-
trols had GG promoter. There were 94.6% with GG TNF-a
(-308 G/A) gene promoter polymorphism and 5.4% with GA
in SLE patients while it was GG in all controls. The two
SLE patients with GA promoter had a higher mean serum le-
vel compared to those with GG promoter.
Similarly, levels of TNF-a are increased in SLE patients
compared with controls but conversely, it was found to
strongly correlate with parameters of disease activity [2,23].
Certain SLE manifestations are associated with differences in
TNF-a production capacity and it has been suggested that
polymorphic elements within or linked to the HLA class II re-
gion determine TNF production capacity [6].polymorphism: Lane (M): 100 bp DNA ladder. Lanes (5–7): GG
ype and (b) IL-6 (-174G/C) gene polymorphism. Lane (M): 50 bp
genotype. Lane (6): CC genotype.
Clinical signiﬁcance of serum TNFa and -308 G/A promoter polymorphism 123The polymorphism on position -308 has been associated
with inducible levels of TNF-a but this association is not well
documented [24] and it contrasts with another study which
suggests that this polymorphism does not affect the TNF pro-
duction [25]. In fact, it was stated that there was no signiﬁcant
association of -308 promoter with disease transmission nor
with a possible protective role in SLE patients [26]. Although
it is unclear whether the TNF-a promoter -308 A/G polymor-
phism has a functional signiﬁcance, several evidences suggest
that there may be a small but signiﬁcant effect with the A allele
[2]. Interestingly, the frequency of the TNF-a -308 polymor-
phism does not change with age among controls; the lack of
matching by age should not introduce bias [2].
Ethnic variation was suggested for the discrepancies in the
results of different studies and the participation of TNF-a
polymorphism in the susceptibility to the disease is unclear.
In Caucasoid SLE patients, a signiﬁcant association with
SLE has been found which could not be revealed in South
African or Mexican patients. [24]. On the other hand, for the
same ethnic populations, the TNF-a promoter -308 A allele
contributed to SLE susceptibility in South African patients
[27], but not in Caucasians [28]. Stratiﬁcation by ethnicity indi-
cated that the risk A allele was not associated with SLE in
Asian and African population [8]. In Taiwanese SLE, no sig-
niﬁcance was observed between TNF-a genotype and SLE
[29]. Moreover, genetic susceptibility to SLE was not associ-
ated with TNF-a gene polymorphism -308 in Thai population
[30]. The association between TNF-a promoter -308A/G poly-
morphism and SLE in Asian populations, especially in Chinese
population has been demonstrated [31] as well as in the Euro-
pean-derived population [2]. Two ethnically different popula-
tions of patients with SLE from the UK and South Africa
were genotyped for TNF-a 308 polymorphisms. At TNF-a
308, the TNF-a variant was signiﬁcantly increased in white pa-
tients with SLE compared to controls. In contrast, in the black
SLE patients the frequency of TNF-a was actually reduced
rather than increased and data indicated that the TNF-308
promoter polymorphism does not confer susceptibility to
SLE [32]. A meta-analysis showed signiﬁcant susceptibility
from TNF-a -308 promoter G/A polymorphism in the Euro-
pean SLE patients but not in Asian or African. The ﬁnding
of the different association according to ethnicity is somewhat
surprising and needs the explanation of why it is not associated
in non-Europeans [2].
There were no other signiﬁcant differences in the character-
istic features of the patients according to the promoter genes.
There were no signiﬁcant correlations of the serum TNF-a
or IL-6 with the clinical or laboratory features of the patients
or according to the anti-ds DNA positivity. According to the
presence or absence of clinical manifestations, there was a ten-
dency to a higher level of IL-6 in those with constitutional
symptoms while the TNF-a level was signiﬁcantly lower in
those with pulmonary manifestations. There was a tendency
to a higher TNF-a and IL-6 level in those with neuropsychiat-
ric manifestations.
In agreement to our results, the serum levels of IL-6, and
TNF-a were signiﬁcantly higher in SLE patients than in con-
trols, however, contrarily a positive correlation was noted
between the level of IL-6 and the activity of the disease [33–
35]. Once this higher serum content of IL-6 was demonstrated,
it might seem contradictory that these patients also presented
high serum levels of TNF-a [36]. The mean level of TNF-awas signiﬁcantly higher in active patients than those with inac-
tive disease and healthy control. Similarly, the mean level of
IL-6 was signiﬁcantly higher in active patients than those with
inactive disease and healthy control. A signiﬁcant correlation
between TNF-a and IL-6 serum levels and the SLEDAI score
were observed. Serum TNF-a and IL-6 are sensitive markers
of SLE disease activity. They may be useful independent mark-
ers for prediction of SLE disease activity and to differentiate
normal subjects from those having SLE. Possible therapeutic
implications in the treatment of SLE in the future deserve wide
scale trials [37]. In another study, lupus nephritis was signiﬁ-
cantly more prevalent among lupus patients possessing the
TNF-a 308 A allele [9].
The mean serum IL-6 was signiﬁcantly higher in the patients
compared to the control. There were 78.38% with GG IL-6
(-174 G/C) with 16.2% with GC and 5.4% with CC promoter
while it was GG in all the control. There was a statistically
signiﬁcant difference between the level in the three groups
according to the promoter polymorphism being lower in those
with GG promoter, and highest in those with CC promoter.
Raised levels of the cytokines IL-6 has been reported in
SLE patients [38]. Levels of IL-6 were signiﬁcantly higher in
SLE patients with active compared with inactive hematological
disease. This association was dependent on an inverse correla-
tion between IL-6 levels and hemoglobin levels in these
patients. Although previous studies have suggested pathogenic
roles for raised levels of IL-6 in SLE, their involvement with
speciﬁc clinical manifestations or disease activity has remained
unclear [38].
An association between higher mean IL-6 levels and active
hematological disease was observed and was not paralleled by
signiﬁcant associations of IL-6 with other clinical activity. In a
previous study using SLEDAI, a lack of correlation between
levels of IL-6 and overall disease activity, was also reported
[39]. The fact that SLE patients with high disease activity have
less expression of TNF-a is not surprising as these patients
were overproducing IL-6, which would inhibit the production
of Th1 cytokines [36].
Because the SLE patients are receiving different treatments,
some drugs such as antimalarials [40,41] or immunosuppres-
sive agents [42] have been reported to inﬂuence cytokine pro-
duction. However, no differences were found both in the
soluble cytokine levels and in the intracellular expression in
T lymphocytes when considering all treatments the SLE
patients were receiving [36]. In disagreement to our results,
there was no statistically signiﬁcant difference in IL-6 gene
polymorphism between the SLE and control groups. While
in agreement, no association between IL-6 genotype and clin-
ical or laboratory proﬁles in SLE patients was detected and
this may suggest that the IL-6 gene polymorphism is not re-
lated to SLE [43].
Psychiatric manifestations are relatively common in SLE
patients. Since there are factors causing psychiatric manifesta-
tions other than SLE, the diagnosis of lupus psychosis (LP) is
often difﬁcult. Cerebrospinal ﬂuid (CSF) IL-6 was elevated in
SLE patients with neuropsychiatric manifestation which might
be an effective measure in diagnosing LP, although exclusion
of infectious meningoencephalitis and cerebrovascular acci-
dent is necessary [44].
The plasma levels of IL-6 in both the inactive and active
SLE patients were signiﬁcantly higher than in the normal con-
trol and it signiﬁcantly positively correlated with SLEDAI
124 G.S. Azkalany et al.scores suggesting that IL-6 might play an important role in the
pathogenesis of SLE [45]. Pathogenic consequences of raised
levels of IL-6 in SLE have been strongly suggested; however,
evidence of any individual organ/system which would respond
to therapeutic manipulation of IL-6 level has not been pro-
vided [38].
In conclusion, serum TNF-a levels and -308 G/A promoter
polymorphism and IL-6 and -174 G/C were higher in SLE
patients than in healthy controls. To conﬁrm our results we
propose that larger scale, multicenter studies with longer eval-
uation periods are needed in selected SLE patients. Additional
studies in a large number of patients may help to establish the
true signiﬁcance of any association. Studies on other genes and
promoter regions may be essential in Egyptian SLE patients to
ﬁnd which one has more relation to SLE disease susceptibility
and clinical manifestations.
Conﬂicts of interest
None.References
[1] Suarez A, Lopez P, Mozo L, Gutierrez C. Differential effect of
IL10 and TNFa genotypes on determining susceptibility to discoid
and systemic lupus erythematosus. Ann Rheum Dis 2005;64:
1605–10.
[2] Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-a promoter -
308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet
2006;14:364–71.
[3] van der Linden MW, van der Slik AR, Zanelli E, Giphart MJ,
Pieterman E, Schreuder GMTh, et al. Six microsatellite markers
on the short arm of chromosome 6 in relation to HLA-DR3 and
TNFa308A in systemic lupus erythematosus. Genes Immun
2001;2(7):373–80.
[4] Fernando MMA, Stevens CR, Sabeti PC, Walsh EC, McWhinnie
AJM, Shah A, et al. Identiﬁcation of two independent risk factors
for lupus within the MHC in United Kingdom families. PLoS
Genet 2007;3(11):e192.
[5] Aguillo´n JC, Cruzat A, Cuenca J, Cuchacovich M. Tumor
necrosis factor alpha genetic polymorphism as a risk factor in
disease. Rev Med Chil 2002;130(9):1043–50.
[6] Rood MJ, van Krugten MV, Zanelli E, van der Linden MW,
Keijsers V, Schreuder GM, et al. TNF-308A and HLA-DR3
alleles contribute independently to susceptibility to systemic lupus
erythematosus. Arthritis Rheum 2000 Jan;43(1):129–34.
[7] Danis VA, Millington M, Hyland V, Lawford R, Huang Q,
Grennan D. Increased frequency of the uncommon allele of a
tumour necrosis factor alpha gene polymorphism in rheumatoid
arthritis and systemic lupus erythematosus. Disease Markers
1995;12:127–33.
[8] Pan HF, Leng RX, Wang C, Qin WZ, Chen LL, Zha ZQ, et al.
Association of TNF-a promoter-308 A/G polymorphism with
susceptibility to systemic lupus erythematosus: a meta-analysis.
Rheumatol Int 2011;April 16 [Epub ahead of print].
[9] Santos MJ, Carmona-Fernandes D, Caetano-Lopes J, Perpe´tuo
IP, Vidal B, Capela S, et al. TNF promoter -308 G> A and LTA
252 A>G polymorphisms in Portuguese patients with systemic
lupus erythematosus. Rheumatol Int 2011;May 5 [Epub ahead of
print].
[10] Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced
systemic lupus erythematosus associated with etanercept therapy.
Lancet 2002;359:579–80.
[11] Aguillo´n JC, Cruzat A, Aravena O, Salazar L, Llanos C,
Cuchacovich M. Could single-nucleotide polymorphisms (SNPs)affecting the tumour necrosis factor promoter be considered as
part of rheumatoid arthritis evolution? Immunobiology
2006;211(1–2):75–84.
[12] Cuenca J, Cuchacovich M, Pe´rez C, Ferreira L, Aguirre A,
Schiattino I, et al. The -308 polymorphism in the tumour necrosis
factor (TNF) gene promoter region and ex vivo lipopolysaccha-
ride-induced TNF expression and cytotoxic activity in Chilean
patients with rheumatoid arthritis. Rheumatology (Oxford) 2003
Feb;42(2):308–13.
[13] Fonseca JE, Santos MJ, Canha˜o H, Choy E. Interleukin-6 as a
key player in systemic inﬂammation and joint destruction.
Autoimmun Rev 2009 Jun;8(7):538–42.
[14] Nile CJ, Read RC, Akil M, Duff GW, Wilson AG. Methylation
status of a single CpG site in the IL6 promoter is related to IL6
messenger RNA levels and rheumatoid arthritis. Arthritis Rheum
2008 Sep;58(9):2686–93.
[15] Perricone C, Ceccarelli F, Valesini G. An overview on the genetic
of rheumatoid arthritis: a never-ending story. Autoimmun Rev
2011;10(10):599–608.
[16] Murakami M, Nishimoto N. The value of blocking IL-6 outside
of rheumatoid arthritis: current perspective. Curr Opin Rheuma-
tol 2011;23(3):273–7.
[17] Hochberg MC. Updating the American College of Rheumatology
revised criteria for the classiﬁcation of systemic lupus erythema-
tosus [letter]. Arthritis Rheum 1997;40:1725.
[18] Bombardier C, Gladman D, Urowitz M, Caron D, Chang C.
Derivation of the SLEDAI. A disease activity index for lupus
patients. The Committee on Prognosis Studies in SLE. Arthritis
Rheum 1992;35:630–40.
[19] Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz
M, et al. The development and initial validation of the Systemic
Lupus International Collaborating Clinics/American College of
Rheumatology damage index for systemic lupus erythematosus.
Arthritis Rheum 1996;39:363–9.
[20] Churg J, Sobin LH. Classiﬁcation of glomerular disease. In:
Churg J, Sobin LH, editors. Renal Disease Classiﬁcation and
Atlas of Glomerular Disease. Tokyo: Igaku Shoin; 1982. p. 3–19.
[21] Dalziel B, Gosby AK, Richman RM, Bryson JM, Caterson ID.
Association of the TNF-alpha (-308 G/A) promoter polymor-
phism with insulin resistance in obesity. Obes Res 2002;10:
401–7.
[22] Pola R, Flex A, Gaetani E, Pola P, Bemabei R. The -174 G/C
polymorphism of the interleukin-6 gene promoter and essential
hypertension in an elderly Italian population. J Hum Hypertens
2002;16(9):637–40.
[23] Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour
necrosis factor a and its soluble receptors parallel clinical disease
and autoimmune activity in systemic lupus erythematosus. Br J
Rheumatol 1996;35:1067–74.
[24] Zu´n˜iga J, Vargas-Alarco´n G, Herna´ndez-Pacheco G, Portal-
Celhay C, Yamamoto-Furusho JK, Granados J. Tumor necrosis
factor a promoter polymorphisms in Mexican patients with
systemic lupus erythematosus (SLE). Genes Immun 2001
Nov;2(7):363–6.
[25] Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al.
Low secretion of tumor necrosis factor alpha, but no other Th1 or
Th2 cytokines, by peripheral blood mononuclear cells correlates
with chronicity in reactive arthritis. Arthritis Rheum
1999;42:2039–44.
[26] Tsuchiya N, Kawasaki A, Tsao BP, Komata T, Grossman JM,
Tokunaga K. Analysis of the association of HLA-DRB1, TNFa
promoter and TNFR2 (TNFRSF1B) polymorphisms with SLE
using transmission disequilibrium test. Genes Immun
2001;2(6):317–22.
[27] Wang M, Dong Y, Huang S. Study on the association between
tumor necrosis factor alpha gene polymorphism and systemic
lupus erythematosus. Zhonghua Nei Ke Za Zhi 1999;38:
393–6.
Clinical signiﬁcance of serum TNFa and -308 G/A promoter polymorphism 125[28] Wilson AG, Gordon C, di Giovine FS, de Vries N, van de Putte
LB, Emery P, et al. A genetic association between systemic lupus
erythematosus and tumor necrosis factor alpha. Eur J Immunol
1994;24:191–5.
[29] Lin YJ, Wan L, Huang CM, Sheu JJ, Chen SY, Lin TH, et al. IL-
10 and TNF-alpha promoter polymorphisms in susceptibility to
systemic lupus erythematosus in Taiwan. Clin Exp Rheumatol
2010;28(3):318–24.
[30] Hirankarn N, Avihingsanon Y, Wongpiyabovorn J. Genetic
susceptibility to SLE is associated with TNF-alpha gene poly-
morphism -863, but not -308 and -238, in Thai population. Int J
Immunogenet 2007;34(6):425–30.
[31] Zou YF, Feng XL, Tao JH, Su H, Pan FM, Liao FF, et al. Meta-
analysis of TNF-alpha promoter -308A/G polymorphism and
SLE susceptibility in Asian populations. Rheumatol Int
2011;31(8):1055–64.
[32] Rudwaleit M, Tikly M, Khamashta M, Gibson K, Klinke J,
Hughes G, et al. Interethnic differences in the association of
tumor necrosis factor promoter polymorphisms with systemic
lupus erythematosus. J Rheumatol 1996;23(10):1725–8.
[33] Houssiau FA, Lefebvre C, Vanden Berghe M, Lambert M,
Devogelaer JP, Renauld JC. Serum interleukin 10 titers in
systemic lupus erythematosus reﬂect disease activity. Lupus
1995;4:393–5.
[34] Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH.
Elevated interleukin-10 levels correlated with disease activity
in systemic lupus erythematosus. Clin Exp Rheumatol
1998;16:283–8.
[35] Waszczykowska E, Robak E, Wozniacka A, Narbutt J, Torzecka
JD, Sysa-Jedrzejowska A. Estimation of SLE activity based on the
serum level of chosen cytokines and superoxide radical generation.
Mediators Inﬂamm 1999;8:93–100.
[36] Mellor-Pita S, Citores MJ, Castejon R, Yebra-Bango M, Tutor-
Ureta P, Rosado S, et al. Monocytes and T lymphocytes
contribute to a predominance of interleukin 6 and interleukin 10
in systemic lupus erythematosus. Cytometry B Clin Cytom
2009;76(4):261–70.[37] Sabry A, Sheashaa H, El-Husseini A, Mahmoud K, Eldahshan
KF, George SK, et al. Proinﬂammatory cytokines (TNF-alpha
and IL-6) in Egyptian patients with SLE: its correlation with
disease activity. Cytokine 2006;35(3–4):148–53.
[38] Ripley BJ, Goncalves B, Isenberg DA, Latchman DS, Rahman
A. Raised levels of interleukin 6 in systemic lupus erythema-
tosus correlate with anaemia. Ann Rheum Dis 2005;64(6):
849–53.
[39] Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L,
Lundberg I. Cytokine production, serum levels and disease
activity in systemic lupus erythematosus. Clin Exp Rheumatol
2000;18:565–70.
[40] Lopez P, Gomez J, Mozo L, Gutierrez C, Suarez A. Cytokine
polymorphisms inﬂuence treatment outcomes in SLE patients
treated with antimalarial drugs. Arthritis Res Ther 2006;8:R42.
[41] Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-
Jedrzejowska A. Chloroquine treatment inﬂuences proinﬂamma-
tory cytokine levels in systemic lupus erythematosus patients.
Lupus 2006;15:268–75.
[42] Su DL, Wang HJ, Ji XH, Li YY, Xuan HB, Heng C, et al.
Mycophenolic acid inhibits SLE-associated cytokine expression
and promotes apoptosis of peripheral blood mononuclear cells
from patients with systemic lupus erythematosus. Acta Pharmacol
Sin 2006;27:1051–7.
[43] Huang CM, Huo AP, Tsai CH, Chen CL, Tsai FJ. Lack of
association of interleukin-6 and interleukin-8 gene polymorphisms
in Chinese patients with systemic lupus erythematosus. J Clin Lab
Anal 2006;20(6):255–9.
[44] Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H,
NPSLE Research Subcommittee. Accuracy of cerebrospinal ﬂuid
IL-6 testing for diagnosis of lupus psychosis. A multicenter
retrospective study. Clin Rheumatol 2009;28(11):1319–23.
[45] Hu S, Xiao W, Kong F, Ke D, Qin R, Su M. Regulatory T cells
and their molecular markers in peripheral blood of the patients
with systemic lupus erythematosus. J Huazhong Univ Sci Technol
Med Sci 2008;28(5):549–52.
